The Theralink® assay may have significant value for triple-negative breast cancer patients
In the I-SPY 2 clinical trial the Reverse Phase Protein Array (RPPA) showed activated HER2 and EGFR levels correlated with response to Neratinib
DENVER, CO / ACCESSWIRE / July 8, 2020 / OncBioMune d/b/a Theralink Technologies (OTC PINK:OBMP), a molecular profiling company specializing in biomarker assay services that target multiple areas of oncology, announced today the signing of a mutli-year strategic agreement with VieCure™ to enhance personalized cancer treatment in community oncology settings.
Theralink Technologies will provide VieCure™ platform users, including Medical Oncologists, with a new and powerful source of precision medicine through dissemination and proper use of its Theralink assay. Theralink is a leading developer of phosphoproteomic technology that can measure the activation state of key cancer drug targets and signaling pathways within a microscopic quantity of a breast cancer tumor sample. Measuring the direct activation state for (or response to) dozens of drug targets at once provides oncologists with key information about the patient’s specific tumor. VieCure has developed a state-of-the-art articficial intelligence platform which combines a smart oncology eMR with the latest clinical guidance (including clinical trials) in the form of codified rules and algorithms. The VieCure™ platform will match relevant patients to the Theralink observational registry clinical trial (known as TRACE) beginning this summer.
The initial use for the TheraLink® assay is for Breast Cancer patients who present with:
- Late stage (stage III-IV) Triple Negative Breast Cancer
- Any stage Inflammatory Breast Cancer
- Metastatic Breast Cancer
- Late stage (stage III-IV) ER+/HER2- Breast Cancer
Electronic interfaces between the VieCure™ platform and the Theralink Lockbox Laboratory Information Management System (LIMS) will be developed and will facilitate the digital exchange of patient data for tumor profiling and Theralink assay results reporting.
“We will be launching our patented, proteomic-based Theralink® assay initially for breast cancer patients, and then planned for most solid tumors, through a prospective, observational registration trial to a select group of oncologists,” said Mick Ruxin, M.D. President and CEO of Theralink Technologies, Inc. “We are very pleased that through our partnership with VieCure, their physician network will have preferred access to the next generation of testing for cancer patients, extending VieCure™ Platform’s genomics information to now include phosphoprotein and protein based information.”
Dr. Joyce O’Shaughnessy, a practicing Medical Oncologist at Texas Oncology, said, “The Theralink assay allows me to understand which protein biomarkers and signaling pathways are active and driving my patient’s metastatic breast cancer growth. Proteomic information can be instrumental in helping guide therapy choices for my patients.”
“The real time information gathered by the oncologist through the use of the Theralink assay and the VieCure smart eMR has the potential to both increase the frequency of actionable findings as well as help physicians make better and more rationalized treatment decisions that can improve treatment outcomes and reduce side effects by foregoing ineffective therapies,” said Dr. Fred Ashbury, Chief Scientific Officer at VieCure.
VieCure will also codify Theralink TRACE clinical protocols within their platform. These algorithms will trigger the participating oncologist to consider putting the relevant breast cancer patient on the Theralink trial where the clinical rules indicate benefit.
The initial term of the agreement is for 5 years with opportunities for renewal and the addition of other disease sites, assays and indications.
VieCure has developed the proprietary VieCureä platform (the “Platform”), a real-time decision-support system that combines clinical knowledge with patient data to assist oncologists in generating personalized treatment plans and managing a patient’s care throughout his or her cancer therapy. The Platform encompasses a proprietary artificial intelligence engine, a knowledge base containing world-leading precision medicine and standard of care guidance and an integrated electronic medical record, specifically created for oncology practices. The platform allows the treatment team to select a preferred course of therapy from a database of treatment plans and modify it as appropriate for the individual patient’s unique circumstances, following best practices including precision medicine options where indicated, as well as institution-specific clinical and financial rules and guidance. Throughout the continuum of care, the platform’s rules-based algorithms suggest therapy adjustments for the treatment team to consider, based on the patient’s test results (including next generation tumor sequencing and proteomics) and specific responses to treatment. The Platform’s embedded eMR functionality includes registration and demographics, scheduling, evaluation and management, toxicity tracking and management, performance status monitoring, orders, pharmacy dispensing, medication administration record, charge capture, progress notes, and flowsheet. It also has a tethered mobile patient app to assist with streamlining communication between providers and patients.
About Theralink Technologies, Inc.
Theralink Technologies is a molecular profiling company, located in Golden, Colorado that specializes in biomarker assay services that target multiple areas of oncology. Theralink provides precision oncology data through its Theralink® assays to assist the biopharmaceutical industry and clinical oncologists in identifying likely responders and non-responders to both FDA-approved and investigational drug treatments. We intend to improve cancer outcomes for patients, reveal therapeutic options for oncologists, and support biopharmaceutical drug development by using a beyond-genomics approach to molecular profiling. For more information, please visit www.theralink.com.
Theralink Technologies, Inc.
KCSA Strategic Communications
Valter Pinto, Managing Director
Client Manager and Marketing Coordinator
Certain statements contained in this press release are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including, without limitation, anything relating or referring to future financial results, patient enrollment and plans for future business development activities, and are thus prospective. Forward-looking statements are inherently subject to risks and uncertainties some of which cannot be predicted or quantified based on current expectations. Such risks and uncertainties include, without limitation, the risks and uncertainties set forth from time to time in reports filed by OncBioMune Pharmaceuticals with the Securities and Exchange Commission. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends affecting the financial condition of our business and although the company believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations will prove to have been correct. Consequently, future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward the forward-looking statements contained herein. The company undertakes no obligation to publicly release statements made to reflect events or circumstances after the date hereof.
View source version on accesswire.com: